Stocktoria
Damora Therapeutics, Inc. DMRA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-10-29
Damora Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D expense | $26.9M | $6.4M | $23.8M | $48.2M | $38.5M | $24.6M | $19.7M |
| Operating income | -$210.9M | -$22.3M | -$39.9M | -$61.2M | -$52.2M | -$33.6M | $39.0M |
| Income tax | $50,000 | $41,000 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$209.8M | -$21.4M | -$38.3M | -$61.6M | -$51.8M | -$34.8M | -$36.5M |
| EPS (diluted) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 | — | — |
| Operating cash flow | -$6.7M | -$18.6M | -$36.9M | -$42.9M | -$52.3M | -$38.2M | -$19.3M |
| Free cash flow | — | — | — | -$43.1M | -$52.5M | — | — |
| Cash & equivalents | $257.6M | $14.2M | $21.5M | $32.8M | $62.6M | $163.6M | $11.3M |
| Total assets | $260.5M | $17.1M | $38.2M | $73.2M | $122.2M | $171.6M | $56.6M |
| Total liabilities | $20.1M | $1.3M | $5.9M | $11.4M | $5.0M | $6.1M | $8.1M |
| Shareholders' equity | $240.4M | $15.8M | $32.3M | $61.8M | $117.2M | $165.5M | -$71.1M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.